The global NGS sample preparation market was valued at USD 1.41 billion in 2021 and is projected to reach USD 5.38 billion by 2030, registering a CAGR of 14.32% from 2022 to 2030. The marketplace for next-technology sequencing (NGS) is developing for some reasons, one every of that's the improvement of merchandise that validates the beginning of creating awesome gene libraries and the sequencing yields. Because of NGS, the observation of genomics has modified a lot. NGS is a current technique that has been verified to collect the entire human genome in only one day. NGS is beneficial for studies and improvement due to the fact it could do sequencing quickly and may be utilized in greater methods. Because sequencing technology is becoming better, there are adjustments being made to the methods samples are processed. Methods utilized in pre-sequencing, along with making libraries and boosting the variety of targets, cause accurate sequencing and awesome data. The marketplace for NGS pattern guidance has been developing at a wholesome price due to the fact there were regular enhancements withinside the field, that has brought about the advent of widespread pattern guidance techniques. The NGS may be used to discover what is incorrect with a person's fitness and to repair troubles with their genes.
Get more information on this report Download Sample Report
During the time covered by the forecast, it is anticipated that the diagnostic phase will enjoy significant growth. Genome sequencing of persons with male or female cancer has been complemented with the use of NGS basic genomic sequencing, which has gotten faster and considerably less expensive with each passing year. This has made it possible for NGS to be utilised currently not only in studies but also in scientific practice. The European Society for Medical Oncology (ESMO) has suggested three different sets of recommendations for the use of next-generation sequencing (NGS) in August of 2020. Based entirely on the information that is currently available, the European Society for Medical Oncology (ESMO) facilitates the routine use of next-generation sequencing (NGS) on tumour specimens for the treatment of non-small cell non-squamous upper lung cancer (NSCLC), cholangiocarcinoma, ovarian cancers, and prostate cancers. It is possible that NGS will replace PCR in the diagnosis of colon cancer. Through the sequencing of hundreds of thousands of DNA reads and the use of healing decision-making, NGS may be suitable for determining the identities of several genes and their alterations at the same time.
Another factor that is boosting the market for NGS sample preparation is the rise in the number of genomic research initiatives being conducted all over the world. The study of genomes has the potential to enlighten us on a great deal of information regarding biology, the history of humans, and distinctions in health, in addition to assisting us in determining the number of significant therapeutic implications. Recent advancements in sequencing technology have made it possible to analyse a patient's full genome and exome within a time period that is clinically helpful. This was previously impossible. Therefore, next-generation sequencing (NGS) is an essential component of diagnosing and monitoring a variety of infectious diseases, which may contribute to the expansion of the market.
One of the biggest problems with the NGS technique is that it makes it more likely to find changes that don't seem to have any clear effect on clinical relevance. Since a huge number of genes are being looked at, it's possible that a lot of surprising things will be found. Some of these results could be risk factors for other diseases or unknown variants. Professionals with a lot of training, like molecular pathologists and clinical geneticists, are needed to figure out how dangerous the variants that have been found are and to tell the difference between those that are dangerous and those that are not. Some very good questions have already been asked about what NGS and genetically overlapping diseases mean for patient care and follow-up. When we find ambiguous results or a "variant of unknown significance" (VUS), we need to be aware of something that has been called "genetic purgatory." The phrase "genetic purgatory" was made up by Ackerman.
The International Agency for Research on Cancer (IARC) predicted in their report "Globocan 2020" that by the year 2020, there will be 19.3 million new cancer cases and 10 million cancer deaths around the world. The International Agency for Research on Cancer says that 1 in 5 people will get some kind of cancer in their lifetime and that 1 in 8 men and 1 in 11 women will die from the disease. Since the number of people getting cancer keeps going up, there is an urgent need for a lot more diagnostic tools that are both fast and accurate.
By product, the NGS sample preparation reagents and consumables segment are expected to grow at the highest rate during the forecast period
Based on the type of product, the market is split into two groups: workstations and reagents and consumables. Based on the workflow, the reagents and consumables sector can be split into the library preparation, target enrichment, and quality control sub-sectors.
This market has grown because of several things, such as the cost of sequencing going down, the availability of advanced and affordable NGS platforms, an increase in the use of NGS in many fields, such as drug and biomarker discovery, diagnostics, agro-genomics, and animal research, an increase in the amount of research that involves sequencing, and the availability of research grants, which are driving the adoption of NGS. All of these things have helped to make this market grow.
By application, the diagnostics segment is expected to be the largest contributor to the NGS sample preparation market
This industry is divided into different submarkets based on how they are used, such as in diagnostics, drug discovery, agricultural and animal research, and other fields. The diagnostics segment is expected to make up the biggest part of the market. This is because more people are being diagnosed with cancer around the world, insurance companies in the US are willing to pay for NGS-based tests, and key market players are putting more effort into making NGS-based products and services for cancer and NIPT.
The market is split by region into North America, Europe, Asia-Pacific, and LAMEA.
Regional Growth Insights Request Sample Pages
North America is the most important area for making money in the NGS sample preparation market around the world. The large share of this regional segment is mostly due to government and private organisations' efforts to develop and use next-generation sequencing (NGS) technologies, the widespread use of NGS diagnostics in the region, the growing number of NGS-based research and clinical applications in the region, more research on cancer, more people becoming aware of NGS services, and the presence of leading NGS service providers.
In December 2020, New England Biolabs launched the NEBNext Custom RNA depletion design tool and RNA depletion core reagent set for customizable RNA depletion
In June 2020, 10x Genomics, Inc. and Merck entered into a collaboration to provide impactful linking of two innovative technologies: single-cell transcriptomics and pooled CRISPR screening and researchers with more detailed information to better understand the relationship between specific genes and disease
In April 2020, Illumina made a software toolkit available free of charge to support the worldwide pandemic of COVID-19.
In February 2019, Agilent Technologies launched NGS library preparation systems which were designed to carry out complex DNA sequencing assays.
In 2018, Thermo Fisher Scientific introduced the Oncomine Childhood Cancer Research Assay which is a next-generation sequencing (NGS) model.